PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS (HIV)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。本研究将评估两种不同的抗HIV药物治疗组合，并将使用两种计划中的一种从一种治疗组合转换为另一种治疗组合。一个计划将转换治疗组合时，病毒载量是1,000份艾滋病毒-1每毫升血液在血液中，另一个计划将转换治疗时，病毒载量是30,000份艾滋病毒-1每毫升血液在血液中。该研究将评估在四年的治疗中，两种转换计划中的任何一种是否有获益差异。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate two different treatment combinations of anti-HIV drugs, and will use one of two plans for switching from one to the other treatment combinations. One plan will switch treatment combination when the viral load is 1,000 copies of HIV-1 per milliliter of blood in the bloodstream, and the other plan will switch treatment when the viral load is 30,000 copies of HIV-1 per milliliter of blood in the bloodstream. The study will evaluate if there is a difference in benefit for either of the two switching plans in a four-year treatment.